PATENT CLAIM ANALYSIS

Application Number: 16050102
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-05
Patent Classification: ["514", "004800"]

Abstract:
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

Claim (Index 25):
An amylin analogue according to  claim 1  which is: (Compound\u20031) (SEQ\u2003ID\u2003NO:\u200355) [19CD]-isoGlu-RD()GTAT-Dap()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u20032) (SEQ\u2003ID\u2003NO:\u200356) [19CD]-isoGlu-RD()GTAT-Dab()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u20033) (SEQ\u2003ID\u2003NO:\u200357) [19CD]-isoGlu-RD()GTAT-Orn()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u20034) (SEQ\u2003ID\u2003NO:\u200358) [19CD]-isoGlu-isoGlu-RD()GTAT-Orn()-ATERLAHFLQRSSF-Gly(Me)-A- Ile(Me)-LSSTEVGSNT-Hyp-NH 2   (Compound\u20035) (SEQ\u2003ID\u2003NO:\u200359) [19CD]-isoGlu-RD()GTAT-Orn()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- PSSTEVGSNT-Hyp-NH 2   (Compound\u20036) (SEQ\u2003ID\u2003NO:\u200360) [19CD]-isoGlu-RD()GTAT-Orn()-ATERLAHFLQRF-Gly(Me)-A-Ile(Me)-LSSTE- VGSNT-Hyp-NH 2   (Compound\u20037) (SEQ\u2003ID\u2003NO:\u200361) [19CD]-isoGlu-RD()GTAT-Orn()-ATERLAHFLHRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNTP-NH 2   (Compound\u20038) (SEQ\u2003ID\u2003NO:\u200362) [19CD]-isoGlu-RD()GTAT-Orn()-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u20039) (SEQ\u2003ID\u2003NO:\u200363) [19CD]-isoGlu-RD()GTAT-Orn()-ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)- PSSTEVGSNT-Hyp-NH 2   (Compound\u200310) (SEQ\u2003ID\u2003NO:\u200364) [19CD]-isoGlu-RD()GTAT-Orn()-ATERLARFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200311) (SEQ\u2003ID\u2003NO:\u200365) [19CD]-isoGlu-ED()GTATK()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTE- VGSNT-Hyp-NH 2   (Compound\u200312) (SEQ\u2003ID\u2003NO:\u200366) [19CD]-isoGlu-RD()GEATK()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTE- VGSNT-Hyp-NH 2   (Compound\u200313) (SEQ\u2003ID\u2003NO:\u200367) [19CD]-isoGlu-RD()GTLTK()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTE- VGSNT-Hyp-NH 2   (Compound\u200314) (SEQ\u2003ID\u2003NO:\u200368) [19CD]-isoGlu-RD()GTASK()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTE- VGSNT-Hyp-NH 2   (Compound\u200315) (SEQ\u2003ID\u2003NO:\u200369) [19CD]-isoGlu-RD()GTATK()ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-PSSTE- VGSNT-Hyp-NH 2   (Compound\u200316) (SEQ\u2003ID\u2003NO:\u200370) [19CD]-isoGlu-RD()GTATK()ATQRLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTE- VGSNT-Hyp-NH 2   (Compound\u200317) (SEQ\u2003ID\u2003NO:\u200371) [19CD]-isoGlu-RD()GTATK()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-PSSTE- VGSNT-Hyp-NH 2   (Compound\u200318) (SEQ\u2003ID\u2003NO:\u200372) [19CD]-isoGlu-RD()GTATK()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTE- VGSNT-Hyp-NH 2   (Compound\u200319) (SEQ\u2003ID\u2003NO:\u200373) [19CD]-isoGlu-RD()GTAT-hLys()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200320) (SEQ\u2003ID\u2003NO:\u200374) [19CD]-isoGlu-RD()GTAT-Orn()-ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200321) (SEQ\u2003ID\u2003NO:\u200375) [19CD]-isoGlu-RD()GTAT-Orn()-ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)- PSSTEVGSNT-Hyp-NH 2   (Compound\u200322) (SEQ\u2003ID\u2003NO:\u200376) [19CD]-isoGlu-RD()GTAT-Orn()-ATERLA-Aad-FLTRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSST-Hyp-NH 2   (Compound\u200323) (SEQ\u2003ID\u2003NO:\u200377) [19CD]-isoGlu-RD()GTAT-Orn()-ATERLA-Aad-FLQRTTF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200324) (SEQ\u2003ID\u2003NO:\u200378) [19CD]-isoGlu-RD()GTAT-Orn()-ATERLA-Aad-FLQRTTF-Gly(Me)-A-Ile(Me)- PSSTEVGSNT-Hyp-NH 2   (Compound\u200325) (SEQ\u2003ID\u2003NO:\u200379) [19CD]-isoGlu-RD()GTAT-Orn()-ATERLA-Aad-FLQRATF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200326) (SEQ\u2003ID\u2003NO:\u200380) [19CD]-isoGlu-RD()GTAT-Orn()-ATERLA-Aad-FLQRAAF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200327) (SEQ\u2003ID\u2003NO:\u200381) [19CD]-isoGlu-RD()GTAT-Orn()-ATERLA-Aad-FLQRGTF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200328) (SEQ\u2003ID\u2003NO:\u200382) [19CD]-isoGlu-RD()QTAT-Orn()-ATERLA-Aad-FLQRGTF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200329) (SEQ\u2003ID\u2003NO:\u200383) [19CD]-isoGlu-RD()PTATK()ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200330) (SEQ\u2003ID\u2003NO:\u200384) [19CD]-isoGlu-ED()GTATK()ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)- PSSTEVGSNT-Hyp-NH 2   (Compound\u200331) (SEQ\u2003ID\u2003NO:\u200385) [19CD]-isoGlu-RD()GTATK()ATERLA-Aad-FLQRAAF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200332) (SEQ\u2003ID\u2003NO:\u200386) [19CD]-isoGlu-RD()GTATK()ATERLA-Aad-FLQRGGF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200333) (SEQ\u2003ID\u2003NO:\u200387) [19CD]-isoGlu-RD()GTATK()ATERLA-Aad-FLQRANF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200334) (SEQ\u2003ID\u2003NO:\u200388) [19CD]-isoGlu-RD()GTATK()ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)- PSSTEVGSNT-Hyp-NH 2   (Compound\u200335) (SEQ\u2003ID\u2003NO:\u200389) [19CD]-isoGlu-RD()GTATK()ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200336) (SEQ\u2003ID\u2003NO:\u200390) [19CD]-isoGlu-RD()GTATK()ATERLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)- LSSTETGSNT-Hyp-NH 2   (Compound\u200337) (SEQ\u2003ID\u2003NO:\u200391) [19CD]-isoGlu-ED()GTATK()ATERLA-Aad-FLQRSSFGly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200338) (SEQ\u2003ID\u2003NO:\u200392) [19CD]-isoGlu-RD()GTATK()ATERLA-Aad-FLORTTF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200339) (SEQ\u2003ID\u2003NO:\u200393) [19CD]-isoGlu-KD()GTATK()ATQRLA-Aad-FLQRSSF-Gly(Me)-AIle(Me)- LSSTEVGSNTHyp-NH 2   (Compound\u200340) (SEQ\u2003ID\u2003NO:\u200394) [19CD]-isoGlu-RD()GTATK()ATQRLA-Aad-FLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200341) (SEQ\u2003ID\u2003NO:\u200395) [19CD]-isoGlu-RD()GTATK()ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTE- VGSNT-Hyp-NH 2   (Compound\u200342) (SEQ\u2003ID\u2003NO:\u200396) [19CD]-isoGlu-RD()GTATK()ATQRLADFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTETGSNT-Hyp-NH 2   (Compound\u200343) (SEQ\u2003ID\u2003NO:\u200397) [19CD]-isoGlu-KD()GTATK()ATQRLANFLQRSSF-Gly(Me)-A-Ile(Me)-LSSTE- VGSNT-Hyp-NH 2   (Compound\u200344) (SEQ\u2003ID\u2003NO:\u200398) [19CD]-isoGlu-KD()GTATK()ATQRLANFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTETGSNT-Hyp-NH 2   (Compound\u200345) (SEQ\u2003ID\u2003NO:\u200399) [19CD]-isoGlu-R-Dap()-GTATD()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200346) (SEQ\u2003ID\u2003NO:\u2003100) [19CD]-isoGlu-R-Dab()-GTATD()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200347) (SEQ\u2003ID\u2003NO:\u2003101) [19CD]-isoGlu-R-Orn()-GTATD()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200348) (SEQ\u2003ID\u2003NO:\u2003102) [19CD]-isoGlu-R-Dap()-GTAT-Aad()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200349) (SEQ\u2003ID\u2003NO:\u2003103) [19CD]-isoGlu-R-Dab()-GTATE()ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200350) (SEQ\u2003ID\u2003NO:\u2003104) [19CD]-isoGlu-R-Aad()-GTAT-Dap()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2   (Compound\u200351) (SEQ\u2003ID\u2003NO:\u2003105) [19CD]-isoGlu-RE()GTAT-Dab()-ATERLAHFLQRSSF-Gly(Me)-A-Ile(Me)- LSSTEVGSNT-Hyp-NH 2 or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 95.0
- Lexical Diversity: 1.4898
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15698743', '14398260', '11278014', '14800627', '15442229']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7932582103054797
- 35 USC 102 Novelty (BERT): 0.7280124623412239
- Combined Prediction Score: 0.7867336355090542
- Mean Citation Score: 487.11570200000006
- Max Citation Score: 847.1067
- Similarity Product: 777.2142534450172

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test